Market Access News | pharmaphorum

News

Alarm bell rung over EU’s unified HTA plan

The EU’s joint clinical assessment (JCA) initiative has been set up to accelerate patient access to new therapies, but could end up restricting the use of new technologies

News

Catalyst throws lifeline to Santhera with $90m Duchenne deal

Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc

News

FDA says no to F2G’s novel antifungal

F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candi

News

AZ may spin off its Chinese business, says report

AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t

News

FDA delays review of GSK’s momelotinib for myelofibrosis

GSK won’t be hearing from the FDA this month about its marketing application for momelotinib as a treatment for myelofibrosis patients with anaemia after all.

News

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

Roche has claimed FDA approval for its CD20xCD3 bispecific antibody Columvi as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), setting up an

Alarm bell rung over EU’s unified HTA plan

Catalyst throws lifeline to Santhera with $90m Duchenne deal

FDA says no to F2G’s novel antifungal

AZ may spin off its Chinese business, says report

FDA delays review of GSK’s momelotinib for myelofibrosis

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks